Compare CCC & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCC | LGND |
|---|---|---|
| Founded | 1980 | 1987 |
| Country | United States | United States |
| Employees | 2185 | 68 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.7B |
| IPO Year | N/A | N/A |
| Metric | CCC | LGND |
|---|---|---|
| Price | $5.31 | $229.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $8.94 | ★ $256.29 |
| AVG Volume (30 Days) | ★ 11.6M | 181.2K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.22 | $1.25 |
| Revenue Next Year | $8.58 | $19.41 |
| P/E Ratio | ★ N/A | $76.27 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.58 | $98.90 |
| 52 Week High | $8.68 | $247.38 |
| Indicator | CCC | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 48.42 | 57.06 |
| Support Level | $4.86 | $180.85 |
| Resistance Level | $6.34 | $247.38 |
| Average True Range (ATR) | 0.29 | 9.57 |
| MACD | 0.02 | -0.53 |
| Stochastic Oscillator | 58.66 | 38.30 |
CCC Intelligent Solutions Holdings Inc is a provider of cloud, mobile, AI, telematics, hyperscale technologies, and applications for the property and casualty insurance economy. The company's SaaS platform connects trading partners, facilitates commerce, and supports mission-critical, AI-enabled digital workflows. It operates in a single segment being Domestic segment, which provides SAAS platform for the P&C insurance economy and derives revenues from providing customers with software subscriptions to the platform in addition to providing professional services and non-software services. The company has its presence in the United States and China. The majority of the revenue is generated from the United States.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.